XML 17 R6.htm IDEA: XBRL DOCUMENT v3.19.2
Consolidated Statements of Equity - USD ($)
$ in Thousands
Total
Total Caladrius Biosciences, Inc. Stockholders' Equity
Series B Convertible Preferred Stock
Series B Convertible Preferred Stock
Common Stock
Additional Paid in Capital
Accumulated Other Comprehensive Loss
Accumulated Deficit
Treasury Stock
Non- Controlling Interest in Subsidiary
Beginning Balance (shares) at Dec. 31, 2017     10,000 9,484,000          
Beginning Balance at Dec. 31, 2017 $ 50,189 $ 50,507 $ 0 $ 9 $ 433,044 $ (28) $ (381,810) $ (708) $ (318)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Net loss (9,062) (9,059)         (9,059)   (3)
Unrealized gain on marketable securities (3) (3)       (3)      
Share-based compensation (in shares)       126,000          
Share-based compensation 1,713 1,713   $ 1 1,712        
Net proceeds from issuance of common stock (in shares)       50,000          
Net proceeds from issuance of common stock 288 288     288        
Proceeds from option exercises (in shares)       75,000          
Proceeds from option exercises 342 342     342        
Change in ownership in subsidiary 0 (48)     (48)       48
Ending Balance (shares) at Jun. 30, 2018     10,000 9,735,000          
Ending Balance at Jun. 30, 2018 43,467 43,740 $ 0 $ 10 435,338 (31) (390,869) (708) (273)
Beginning Balance (shares) at Mar. 31, 2018     10,000 9,575,000          
Beginning Balance at Mar. 31, 2018 45,316 45,588 $ 0 $ 10 433,138 (59) (386,793) (708) (272)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Net loss (4,077) (4,076)         (4,076)   (1)
Unrealized gain on marketable securities 28 28       28      
Share-based compensation (in shares)       47,000          
Share-based compensation 1,610 1,610     1,610        
Net proceeds from issuance of common stock (in shares)       50,000          
Net proceeds from issuance of common stock 288 288     288        
Proceeds from option exercises (in shares)       63,000          
Proceeds from option exercises 302 302     302        
Ending Balance (shares) at Jun. 30, 2018     10,000 9,735,000          
Ending Balance at Jun. 30, 2018 43,467 43,740 $ 0 $ 10 435,338 (31) (390,869) (708) (273)
Beginning Balance (shares) at Dec. 31, 2018     10,000 9,866,000          
Beginning Balance at Dec. 31, 2018 37,454 37,726 $ 0 $ 10 436,433 (32) (397,977) (708) (272)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Adoption of accounting standard (62) (62)         (62)    
Net loss (9,502) (9,507)         (9,507)   5
Unrealized gain on marketable securities 32 32       32      
Share-based compensation (in shares)       96,000          
Share-based compensation 663 663     663        
Net proceeds from issuance of common stock (in shares)       451,000          
Net proceeds from issuance of common stock 1,037 1,037     1,037        
Ending Balance (shares) at Jun. 30, 2019     10,000 10,413,000          
Ending Balance at Jun. 30, 2019 29,622 29,889 $ 0 $ 10 438,133 0 (407,546) (708) (267)
Beginning Balance (shares) at Mar. 31, 2019     10,000 10,393,000          
Beginning Balance at Mar. 31, 2019 34,458 34,728 $ 0 $ 10 437,850 (18) (402,406) (708) (270)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Net loss (5,137) (5,140)         (5,140)   3
Unrealized gain on marketable securities (5,137)         18      
Share-based compensation 18 18              
Net proceeds from issuance of common stock (in shares)       0          
Net proceeds from issuance of common stock 246 246     246        
Proceeds from option exercises (in shares)       20,000          
Proceeds from option exercises 37 37     37        
Ending Balance (shares) at Jun. 30, 2019     10,000 10,413,000          
Ending Balance at Jun. 30, 2019 $ 29,622 $ 29,889 $ 0 $ 10 $ 438,133 $ 0 $ (407,546) $ (708) $ (267)